Marshall Edwards, Novogen preclinical data

In mouse xenograft models of ovarian cancer, NV-128 reduced tumor volume by 51% relative to untreated mice at 15 days compared with 50% for rapamycin. At 21 days, tumor mass was reduced by 41% and 44%...